AstraZeneca plc (AZN) Ordinary US$0.25
Share news, reports & tips
25 February 2020 13:15
(Sharecast News) - Redrow: Jefferies upgrades to buy with a target price of 981p.
25 February 2020 07:30
(Sharecast News) - AstraZeneca has agreed to sublicense its global rights to 'Movantik', or naloxegol, excluding Europe, Canada and Israel, to RedHill Biopharma, it announced on Tuesday.
20 February 2020 13:40
(Sharecast News) - Travis Perkins: Citigroup upgrades to buy with a target price of 1,900p.
19 February 2020 16:50
(Sharecast News) - AstraZeneca revealed on Wednesday that non-executive director Michel Demare had acquired 700 ordinary shares in the FTSE 100-listed pharmaceutical giant.
17 February 2020 13:05
(Sharecast News) - Hikma Pharmatheuticals: Citigroup downgrades to neutral with a target price of 1,980p.
14 February 2020 11:27
(Sharecast News) - Stocks have recovered from an early dip after the World Health Organisation said overnight that the spike in coronavirus cases in China on Thursday are not new infections.
14 February 2020 08:00
(Sharecast News) - Stocks slipped in early trading as traders grappled with the difficulty of pinpointing how far along China really was in controlling the outbreak of a new coronavirus in the country.
14 February 2020 07:03
(Sharecast News) - AstraZeneca's annual profit fell 14% as rising costs and higher asset writedowns offset sales increases at the pharmaceutical company.
27 January 2020 09:24
(Sharecast News) - AstraZeneca said high-level results from from a phase three trial of its Brilinta drug used in conjunction with aspirin produced a "statistically significant and clinically...
27 January 2020 07:53
(Sharecast News) - AstraZeneca said it had agreed to sell the global commercial rights to a range of hypertension treatments to Atnahs Pharma for up to $390m.
22 January 2020 12:52
(Sharecast News) - Experian: Morgan Stanley upgrades to overweight with a target price of 2,950p.
20 January 2020 07:19
(Sharecast News) - AstraZeneca announced on Monday that its 'Imfinzi' (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted orphan drug...
Company announcements Announcements
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see http://www.DigitalLook.com/newsfeedterms for our terms and conditions.
© Digital Look Ltd 1998-2020. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.